Invention Grant
- Patent Title: Pyrrolo[3,2-c][2,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors
-
Application No.: US18242759Application Date: 2023-09-06
-
Publication No.: US11891377B1Publication Date: 2024-02-06
- Inventor: Michelyne Haroun , Christophe Tratrat
- Applicant: KING FAISAL UNIVERSITY
- Applicant Address: SA Al-Ahsa
- Assignee: KING FAISAL UNIVERSITY
- Current Assignee: KING FAISAL UNIVERSITY
- Current Assignee Address: SA Al-Ahsa
- Agency: Nath, Goldberg & Meyer
- Agent Richard C. Litman
- Main IPC: C07D401/14
- IPC: C07D401/14 ; A61P35/02 ; A61P35/00
![Pyrrolo[3,2-c][2,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors](/abs-image/US/2024/02/06/US11891377B1/abs.jpg.150x150.jpg)
Abstract:
Novel pyrrolo[3,2-c][2,7]naphthyridine-2-carboxylic acid compounds, a method of synthesizing these compounds, a pharmaceutical composition comprising these compounds and a suitable carrier, and a method of using the compounds. The pyrrolo[3,2-c][2,7]naphthyridine-2-carboxylic acid compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.
Information query